Effectiveness and Safety of Dapagliflozin for Black and White ...

This is a substudy of the DAPA-CKD trial (NCT03036150) that investigated the effectiveness and safety of dapagliflozin for patients with CKD.

Effectiveness and Safety of Dapagliflozin for Black vs White Patients ...

Effectiveness and safety of dapagliflozin for black vs white patients with chronic kidney disease in North and South America.

Effectiveness and Safety of Dapagliflozin for Black vs White Patients ...

Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary ...

Efficacy and Safety of Dapagliflozin in Black vs. White Patients With ...

Black and White patients experienced similar clinical benefits with dapagliflozin including fewer kidney and cardiovascular events and prolonged survival.

Efficacy of Dapagliflozin in Black Versus White Patients With Heart ...

Black patients had a higher rate of worsening HF events, but not mortality, compared with White patients. Compared with placebo, dapagliflozin reduced the risk ...

Dapagliflozin in Black and White Patients With HF

The absolute benefits of the SGLT2 inhibitor dapagliflozin is greater in Black patients in part due to having a higher incidence and prevalence of heart ...

Dapagliflozin in Black and White Patients With Heart Failure Across ...

Compared with placebo, dapagliflozin decreased the risk of the primary endpoint to the same extent in Black (HR: 0.69; 95% CI: 0.47-1.02) and ...

Dapagliflozin in Black and White Patients With Heart Failure Across ...

Compared with placebo, dapagliflozin decreased the risk of the primary endpoint to the same extent in Black (HR: 0.69; 95% CI: 0.47-1.02) and White patients (HR ...

Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney ...

Dapagliflozin reduced the risk of the primary composite endpoint across all FI categories (hazard ratios [95% confidence interval {CI}]: 0.50 [0.33–0.76], 0.62 ...

(PDF) Efficacy of Dapagliflozin in Black Versus White Patients With ...

Compared with placebo, dapagliflozin decreased the risk of the primary endpoint to the same extent in Black (HR: 0.69; 95% CI: 0.47-1.02) and ...

Empagliflozin in Black Versus White Patients With Heart Failure

In the pooled analysis, there was a concordant efficacy of empagliflozin on the primary outcome in Black patients versus White patients (0.56 [ ...

Efficacy and Safety of Dapagliflozin in Patients With Inadequately ...

Dapagliflozin as adjunct therapy to adjustable insulin in patients with type 1 diabetes was well tolerated and improved glycemic control with no ...

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved ...

Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients ...

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced ...

The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other ...

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status

The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular ...

Effectiveness and Safety of Dapagliflozin for Black vs White Patients ...

Request PDF | Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary ...

Omitted Study Rationale and Acknowledgment of Race as a Social ...

In the Research Letter “Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South ...

Dapagliflozin in Black and White Patients With Heart Failure Across ...

This study shows that dapagliflozin is an effective treatment for HF in both Black and White patients. These findings highlight the importance ...

Dapagliflozin in Patients with Heart Failure and Reduced Ejection ...

We designed the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial to prospectively evaluate the efficacy and safety of the SGLT2 ...

Efficacy and Safety of Dapagliflozin According to Frailty in Heart ...

Dapagliflozin improved all outcomes examined, regardless of frailty status. However, the absolute reductions were larger in more frail patients.